Trials in humans of a potential coronavirus vaccine by German biotech firm BioNTech and US pharmaceutical giant Pfizer has shown potential, the two firms announced recently.
The drug is one of 17 being tested on humans in a frantic global race to find a vaccine the world is counting on to end a pandemic that has infected 10.5 million people and killed more than half a million so far.
The potential treatment is the fourth early-stage COVID-19 drug to show promise in human testing, along with projects involving Moderna, CanSino Biologics and Inovio Pharmaceuticals.
BioNTech’s shares were up about 8%, after rising as much as 19% to reach their highest in more than three months.
Pfizer stock also gained, rising 4.4% to $34.13. In turn, shares in some rival vaccine developers, such as Moderna and Novavax Inc dropped.
BioNTech said testing of two dosages of its BNT162b1 drug on 24 healthy volunteers showed that after 28 days they had developed higher levels of COVID-19 antibodies than typically seen in infected people.
It said the higher of the two doses — both administered via two injections within three weeks of one another — was followed by a short fever in three out of four participants after the second shot.
A third dosage, tested at a higher concentration in a separate group, was not repeated after the first shot because of injection pain.
“These first trial results show that the vaccine yields immune activity and causes a strong immune response,” said BioNTech’s co-founder and Chief Executive Officer Ugur Sahin.
He said larger trials were being prepared to show whether this translates into protection against a real infection.
“While more work needs to be done, we believe the benefits appear to outweigh the risks so far, especially when considering the disease the vaccine is trying to prevent,” Mizuho Securities analyst Divan Vamil said in a note.
Bernstein analysts said their initial impression was that the data was “solid”, but noted they don’t expect the initial generation of vaccines to be silver bullets in terms of conferring nearly complete protection.
Peer review
No COVID-19 vaccine has yet been approved for commercial use. A Massachusetts Institute of Technology analysis last year found that about one in three vaccines in the first stage of testing later gains approval.
BioNTech, which listed on the US Nasdaq in October, said the data demonstrated that BNT162b1 could be administered in a dose that was well tolerated with only temporary side effects.
Early-stage human trials of vaccines are designed to measure certain antibodies and other immune markers in the blood as an indicator of the body’s readiness to fight an infection that then requires further validation.
The pharmaceutical industry is eager to launch larger follow-up trials to see how vaccinated participants react to real infections over longer periods.
Brokerage SVB Leerink said these larger studies are required for vaccine approval and adoption, and the timing for approval will be dependent on the trials and their results, and not more abbreviated smaller interim studies.
BioNTech and Pfizer will now pick the most promising of four experimental vaccines for a trial involving up to 30,000 healthy participants, which is likely to begin in the United States and Europe in late July, if it gets the regulatory green light.
If it eventually gets marketing approval, the companies are gearing up to make up to 100 million doses by the end of 2020 and another 1.2 billion doses by the end of 2021 at sites in Germany and the United States.
Results from early-stage testing of BioNTech’s three other potential vaccines are yet to be published.
The manuscript with the preliminary data from the clinical trials, which were launched in April and May, is under peer review for publication in a scientific journal, BioNTech said.
The Mainz-based company is using the so-called messenger RNA approach, like unlisted domestic rival CureVac and Moderna. Translate Bio and its partner Sanofi are also working on a messenger RNA vaccine for COVID-19. Biotech investors Thomas and Andreas Struengmann, who sold their generic drugs business Hexal to Novartis in 2005, are major shareholders of BioNTech.
-Courtesy by Reuters
